Results 241 to 250 of about 1,067,278 (309)

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Improving the protein quality of New Zealand vegan diets: an optimisation modelling approach incorporating energy constraints and diet acceptability. [PDF]

Front Nutr
Soh BXP, Vignes M, Smith NW, von Hurst PR, McNabb WC.   +4 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Development and Psychometric Validation of a Usability Instrument Based on ISO 25010 for Electronic Health Record Systems in Peruvian Health Care Settings: Methodological Study. [PDF]

JMIR Hum Factors
Mamani-Pari D, Peñaloza-Hualpa AF, Humpiri-Flores ME, Gutierrez-Quispe E, Otazu-Luque JE.   +4 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Protein Paradox: Protein Quality Based on Amino Acids Composition is Poorly Associated with Health Outcomes. [PDF]

Curr Nutr Rep
López-Moreno M, Barrantes-Espinola G, Craddock JC.   +2 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Toward a Common Set of Interface Requirements for Genomic Data Management: Scoping Review. [PDF]

J Med Internet Res
Resendez V, Yıldırım F, Gaeta E, Fico G, Borsci S.   +4 more
europepmc   +1 more source

Journal research data policies in materials science.

Digit Discov
Hörmann L, Myneni H, Al-Hamd RKS, Batalović K, Bonfanti S, Grasselli F, Gražulis S, Koç B, Konstantinou K, Lončarić I, Lopanitsyna N, Oliveira JM, Pegolo P, Ramos P, Rossi K, Schwaminger SP, Simmen E, Todorović M, Stricker M, Schmidt J.   +19 more
europepmc   +1 more source